美丽田园业绩预告出“乌龙” 净利润“亿元”秒变“千万元”

Core Viewpoint - The article highlights the importance of accurate and responsible information disclosure by listed companies, using the case of Meili Tianyuan Medical Health Industry Co., Ltd. as an example of a company that made significant errors in its financial announcements, reflecting a lack of rigor in its reporting practices [1][2]. Financial Performance - Meili Tianyuan's preliminary performance forecast indicated expected revenue of at least RMB 14.5 billion for the six months ending June 30, 2025, representing a growth of at least 27% compared to the same period in 2024 [2]. - The adjusted net profit was initially reported as at least RMB 17.5 million, later corrected to RMB 175 million, showing a growth of at least 33% year-on-year [2][3]. - The company reported a net profit of at least RMB 17 million, later corrected to RMB 170 million, reflecting a growth of at least 35% compared to 2024 [2][3]. Business Strategy - Meili Tianyuan employs a "dual growth" strategy of "internal growth + external mergers," which has led to significant business expansion and market share increase [2][4]. - The company has seen steady growth in revenue and net profit since its listing, with revenues of RMB 21.45 billion and net profits of RMB 2.3 billion in 2023, and projected revenues of RMB 25.72 billion and net profits of RMB 2.52 billion in 2024 [4]. Market Position - The acquisition of a 70% stake in the second-largest beauty brand, Nairui Health Technology Co., Ltd., for RMB 350 million has enhanced Meili Tianyuan's market position and contributed to its revenue growth [4][5]. - As of December 31, 2024, the company had over 554 stores across more than 100 cities, indicating a robust expansion of its operational footprint [4]. Stock Market Performance - As of August 8, the stock price of Meili Tianyuan was HKD 27.2 per share, with a total market capitalization of HKD 64.14 billion [6].